Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Clinical Significance of Increased Ki-67 Protein Expression in Non-small Cell Lung Cancers

비소세포폐암 환자에시 Ki-67 단백질 발현증가의 임상적 의의

  • Lee Gun (Department of Thoracic and Cardiovascular Surgery, Pochon CHA Medical University) ;
  • Lim Chang-Young (Department of Thoracic and Cardiovascular Surgery, Pochon CHA Medical University) ;
  • Kim Kwang-Il (Department of Pathology, Pochon CHA Medical University) ;
  • Lee Hyeon-Jae (Department of Thoracic and Cardiovascular Surgery, Pochon CHA Medical University)
  • 이건 (포천중문의과대학교 흉부외과학교실) ;
  • 임창영 (포천중문의과대학교 흉부외과학교실) ;
  • 김광일 (포천중문의과대학교 병리학교실) ;
  • 이헌재 (포천중문의과대학교 흉부외과학교실)
  • Published : 2006.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The Ki-67 protein is a biomarker associated with cell proliferation and a valuable negative prognostic factor in non-small cell lung cancer. We investigated the Ki-67 protein expression in resected non-small cell lung cancer to evaluate the impact on clinicopathological characteristics and postoperative prognosis. Material and Method: Using monoclonal antibody Ki-67, we immunohistochemically examined 38 surgically resected non-small ceil lung cancers to determine Ki-67 Labeling Index (LI). We analysed the differences of clinicopathological characteristics and postoperative recurrence and survival between High Ki-67 Group $(LI{\ge}20%)$ and Low Ki-67 Group (LI<20%). Result: The Ki-67 LIs were heterogenous and a mean values was $20.0{\pm}20.05%$. There were no significant differences in age, sex, smoking, TNM stage, and vascular invasion between High Ki-67 Group and Low Ki-67 Group. A High Ki-67 Group was significantly associated with squamous cell type, poor differentiation, and lymphatic invasion $(p{\le}0.05)$. High Ki-67 Group showed a trend of lower survival (median 47.2 vs. 90.5 months, p=0.312) and lower disease-free survival (median 18.2 vs. 72.3 months, p=0.327) than Low Ki-67 Group. Conclusion: These results indicate that increased Ki-67 protein expression may be a negative prognostic factor and showed a trend of shortened survival and disease-free survival. To evaluate the pivotal role of Ki-67 protein expression, a long-term follow-up and further study are required.

배경: Ki-67 단백질은 세포의 증식활성도를 나타내는 생물표식자로, 비소세포폐암 환자에서 Ki-67 단백질의 증가는 예후에 나쁜 영향을 미치는 것으로 알려져 있다. 이 연구는 비소세포폐암으로 폐절제술을 실시한 환자에서 Ki-67 단백질의 발현정도를 조사하여, 단백질의 발현증가가 환자의 임상적 병리적 양상과 술 후 재발과 생존기간에 미치는 영향을 알아보기 위해 시행되었다. 대상 및 방법: 근치적 폐절제술을 실시한 38명의 비소세포폐암 조직에서 단클론항체 Ki-67로 면역조직화학염색을 실시하여 Ki-67 Labeling Index (LI)를 구하였다. 환자를 Ki-67 증가군$(LI{\ge}20%)$과 Ki-67 비증가군(LI<20%)으로 분류하여, 두 군의 술 전 임상적 병리적 특성, 술 후 생존기간 및 무병생존기간을 비교하였다. 결과: Ki-67 LI는 불균질한 분포를 보였고 평균 LI는 $20.0{\pm}20.1%$였다. Ki-67 증가군과 비증가군 간에나이, 성별, 흡연, TNM 병기, 혈관침윤은 유의한 차이가 없었다. 그러나 증가군은 비증가군에 비해 편평상피암이 많고, 분화도가 나쁘며, 임파침윤이 많았다$(p{\le}0.05)$. 증가군은 중앙 생존기간(47.2 vs. 96.5개월)과 중앙 무병생존기간(18.2 vs. 72.3개월)이 비증가군보다 짧았으나 통계적 유의성은 없었다(각각 p=0.312, p=0.327). 결론: 이상의 연구를 통해 비소세로폐암 환자에서의 Ki-67 단백질 발현증가는 수술 후 환자의 예후에 나쁜 인자로 작용하여 생존기간과 무병생존기간이 짧아지는 경향을 보였으나 통계적 유의성이 부족하여 향후 지속적인 연구가 필요할 것이다.

Keywords

References

  1. Lad T, Rubistein L, Sadeghi A. The benefit of adjuvant treatment for resectable locally advanced non-small cell lung cancer. J Clin Oncol 1988;6:9-17 https://doi.org/10.1200/JCO.1988.6.1.9
  2. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Steven A. Cancer principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers. 1997;858-910
  3. Socinski MA. Adjuvant therapy of resected non-small cell lung cancer. Clin Lung Cancer 2004;6:162-9 https://doi.org/10.3816/CLC.2004.n.029
  4. Hunter T, Pines J. Cyclins and cancer.II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82 https://doi.org/10.1016/0092-8674(94)90543-6
  5. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7 https://doi.org/10.1126/science.274.5293.1672
  6. Minna, JD, Sekido Y, Fong KM, Gazdar AF. Molecular biology of lung cancer. In: DeVita VT Jr, Hellman S, Steven A. Cancer: principles & practice of oncology. 5th ed. Philadelpha: Lippincott-Raven Publishers. 1997;849-57
  7. Gupta AK, Harris EER, BArnhard EJ, et al. Overview of cell cycle and apoptosis. In: Pass HI, Mitchell JB, Johnson DH, Turris AT, Minna JD. Lung cancer. Principle and practice. Philadelphia: Lippincott Williams & Wilkins. 2000;5-67
  8. Forgacs E, Zochbauer-Muller S, Olan E, Minna JD. Molecular genetic abnormalities of human lung cancer. Pathol Oncol Res 2001;7:6-13 https://doi.org/10.1007/BF03032598
  9. Dobash Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclinA-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomaas. Am J Pathol 1998;84:49-53
  10. Kawabuchi B, Moriyama S, Hirinaka M, et al. p16 inactivation in small-sized lung adenocarcinoma; its association with poor prognosis. Int J Cancer 1999;84:49-53 https://doi.org/10.1002/(SICI)1097-0215(19990219)84:1<49::AID-IJC10>3.0.CO;2-Y
  11. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunology 1984;133:1710-5
  12. Scott RJ, Hall PA, Haldane JS, et al. A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 1991;165: 173-8 https://doi.org/10.1002/path.1711650213
  13. Gerdes J, Stein H, Pilen S, et al. Prognostic relevance of tumor-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;2:448-9
  14. Hall PA, Gregory W, Richards MA, d'Ardenne AJ, Lister TA, Stansfield AG. The prognostic significance of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988; 54:223-35
  15. Hall PA, Levison DA. Assessment of cellular proliferation in histological material. J Clin Pathol 1990;43:184-92 https://doi.org/10.1136/jcp.43.3.184
  16. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Research 2000; 6:4073-81
  17. Niemiec J, Kolodziejski L, Dyczek S. EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 2005;52:231-7
  18. Viberti L, Papotti M, Abbona GC, Celano A, Filosso PL, Bussolati G. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of lung. Hum Pathol 1997;28:189-92 https://doi.org/10.1016/S0046-8177(97)90105-2
  19. Mehdi SA, Etzell JE, Newman NB, Kohman LJ, Graziano SL. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung cancer 1998;20:99-108 https://doi.org/10.1016/S0169-5002(98)00027-0
  20. Kawama H, Tamaru J, Tanaka T, et al. Role of p27kip1 and cyclin dependent kinase 2 in the proloferation of non-small cell lung cancer. Am J Pathol 1998;153:505-13 https://doi.org/10.1016/S0002-9440(10)65593-9